Wednesday 16 September 2026

The Pharma Letter Podcast — Episode 15 — Can AI find new drugs for metabolic diseases?

Pharmaceutical
4 July 2022
episode15-big

More on this story...

Pharmaceutical
The FDA and artificial intelligence
7 June 2021
Pharmaceutical
European drugmakers embrace artificial intelligence
3 December 2020
Pharmaceutical
Is AI patentable?
5 July 2022
Pharmaceutical
Understanding the AI-enabled drug discovery landscape
8 July 2022




More ones to watch >




Today's issue

RegCell banks $66 million to take Nobel-winning Treg work into clinic
Biotechnology
RegCell banks $66 million to take Nobel-winning Treg work into clinic
16 September 2026
Pharmaceutical
Realizing the promise of RWE: A need for greater regulatory clarity
16 September 2026
Pharmaceutical
Diasome reshapes leadership team as HDV-Insulin heads toward Phase III
15 September 2026
Generics
Sandoz issues 500 million euros bond to extend debt maturity profile
15 September 2026
Biotechnology
GSK punts $750M on TCE for multiple myeloma from Chimagen
15 September 2026
Biotechnology
Hummingbird names James Garner as president
15 September 2026
Pharmaceutical
Chiesi names David Khougazian as group CEO, succeeding interim chief
15 September 2026


Company Spotlight

Telix Pharmaceuticals
A commercial-stage Australian biopharmaceutical company building a vertically integrated theranostics franchise across prostate cancer, renal cell carcinoma, and neuro-oncology through FDA-approved PSMA imaging agents and an advancing radiotherapeutic pipeline.


More Features in Pharmaceutical

Ascendis regains obesity rights as Novo exits monthly GLP-1 deal
16 September 2026
Realizing the promise of RWE: A need for greater regulatory clarity
16 September 2026
Diasome reshapes leadership team as HDV-Insulin heads toward Phase III
15 September 2026
Chiesi names David Khougazian as group CEO, succeeding interim chief
15 September 2026


Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze